Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Madrigal Pharmaceuticals, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must be willing to participate in the study and provide written informed consent.
Male and female adults ≥18 years of age.
Suspected or confirmed diagnosis of NASH or NAFLD (presumed NASH):
* Fibroscan with kPa ≥5.5 and \<8.5; CAP ≥280 dB.m-1 OR
* MRE ≥2 and \<4.0; MRI-PDFF ≥8% liver fat consistent with steatosis and fibrosis stage ≥1 and \<4. OR
* Recent liver biopsy (within past 2 years) documenting NASH/NAFLD with steatosis showing one of the following:
* NAS ≥4, steatosis ≥1, fibrosis stage 0 or F1A/1C with PRO-C3 \<14
* NAS \<4, steatosis ≥1, with fibrosis stage ≤3
* NAS ≥4, steatosis ≥1, fibrosis stage ≤3 without ballooning
* NOTE: Since the completion of enrollment of the double-blind arms, patients meeting all other criteria who have a liver biopsy result from MGL-3196-11 with the following may be enrolled in the open-label active treatment arm of MGL-3196-14 (100 mg dose):
* NAS = 3, steatosis 1, ballooning 1, inflammation 1 with F2 or F3
* NAS = 3, ballooning 0 with F2 or F3
* For the compensated NASH cirrhosis arm, eligible patients must have compensated NASH cirrhosis diagnosed by liver biopsy showing NASH with F4 stage fibrosis (either historic or recent biopsy) or a historic biopsy with NASH F2-F3 fibrosis with subsequent progression to NASH cirrhosis as diagnosed by an expert hepatologist/gastroenterologist.
* Compensated NASH cirrhosis at screening and baseline includes
* Child Pugh-A (score 5-6) ( may have either mild hepatic encephalopathy OR mild diuretic responsive ascites OR albumin \< 3.5 and ≥ 3.2 (not any two of these, unless explained by Gilbert's Syndrome or non-hepatic causes)).
* MELD \< 12 at screening/baseline unless MELD ≥ 12 based on non-cirrhotic parameters (e.g., elevated INR due to anticoagulation, bilirubin elevation due to documented Gilbert's Syndrome, elevated creatine due to renal disease (non-hepatic)).
MRI-PDFF fat fraction ≥8% obtained during the Screening Period (baseline MRI-PDFF) or a historic MRI-PDFF ≤8 weeks old at the time of randomization.
Stable dyslipidemia therapy for ≥30 days prior to randomization.
You may not be if
History of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to Screening.
Regular use of drugs historically associated with NAFLD.
History of bariatric surgery or intestinal bypass surgery within the 5 years prior to randomization or planned during the conduct of the study.
Weight gain or loss ≥5% total body weight within 12 weeks prior to randomization.
HbA1c \>9.0%.
Glucagon-like peptide 1 \[GLP-1\] agonist therapy or high dose vitamin E (\>400 IU/day) unless stable for 24 weeks prior to biopsy.
Presence of cirrhosis on liver biopsy defined as stage 4 fibrosis.
Diagnosis of hepatocellular carcinoma (HCC).
Model for End-stage Liver Disease (MELD) score ≥12, as determined at Screening, unless due to therapeutic anti coagulation or Gilbert syndrome.
Hepatic decompensation.
Chronic liver diseases.
Has an active autoimmune disease.
Serum ALT \>250 U/L.
History of biliary diversion.
Uncontrolled hypertension (either treated or untreated).
Active, serious medical disease with a likely life expectancy \<2 years.
Participation in an investigational new drug trial in the 60 days or 5 half-lives, whichever is longer, prior to randomization.
Any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, compromise the well-being of the patient, or interfere with the study outcomes.
Clareo Health | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
